Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 13, Issue 9A, Pages 2780-2786Publisher
WILEY
DOI: 10.1111/j.1582-4934.2009.00876.x
Keywords
HIF-1; hypoxia; cancer therapy
Categories
Funding
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
Ask authors/readers for more resources
Introduction Mechanisms of action of action of HIF-1 inhibitors Inhibitors of HIF-1 alpha mRNA expression Inhibitors of HIF-1 alpha protein translation Inhibitors that affect HIF-1 alpha degradation pathway Inhibitors of HIF-1 binding to DNA Inhibitors of HIF-1 alpha transcriptional activity Conclusions Intratumour hypoxia has long been considered a driving force of tumour progression and a negative prognostic factor in human cancers. The discovery of hypoxia inducible factors (HIFs), which mediate transcriptional responses to changes in oxygen levels, has renewed enthusiasm for the discovery and development of targeted therapies exploiting the hypoxic tumour microenvironment. In spite of an ever increasing number of putative small molecule inhibitors of HIF, only few progress through pre-clinical and early clinical development. In this review, we will focus primarily on: (1) HIF inhibitors that have been more recently described and (2) small molecules targeting HIF that are being tested in early clinical trials or that are already approved for use in patients. A rigorous 'validation' of HIF targeted therapies in relevant pre-clinical models and eventually in pharmacodynamic-based early clinical trials is essential for 'credentialing' HIF-1 as a legitimate target that can be pharmacologically modulated in cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available